Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience

BACKGROUND: In GM1 gangliosidosis the lack of function of β‐galactosidase results in an accumulation of GM1 ganglioside and related glycoconjugates in visceral organs, and particularly in the central nervous system, leading to severe disability and premature death. In the type 2 form of the disease,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Genet Genomic Med
Main Authors: Fischetto, Rita, Palladino, Valentina, Mancardi, Maria M., Giacomini, Thea, Palladino, Stefano, Gaeta, Alberto, Di Rocco, Maja, Zampini, Lucia, Lassandro, Giuseppe, Favia, Vito, Tripaldi, Maria E., Strisciuglio, Pietro, Romano, Alfonso, Severino, Mariasavina, Morrone, Amelia, Giordano, Paola
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Clinical Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549581/
https://ncbi.nlm.nih.gov/pubmed/32779865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mgg3.1371
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki